01273 704473

info@novuscomms.com

01273 704473

info@novuscomms.com

#ELEG Electric Guitar PLC – Scheduled Suspension of trading on AIM June 25, 2025 – Posted in: Electric Guitar Plc (ELEG)

Trading in the ordinary shares of Electric Guitar PLC (LSE: ELEG) is expected to be suspended at 07.30 today, 25 June 2025, in accordance with Rule 15 of the AIM Rules for Companies (the “AIM Rules”) and in line with the timetable previously announced.   Electric Guitar plc became an AIM Rule 15 cash shell on 24 December 2024 and, as such, the Company was required to make an acquisition or acquisitions which constitute a…

Continue reading

#POLB Poolbeg Pharma PLC – Voluntary Delisting from OTCQB Market July 26, 2024 – Posted in: Poolbeg Pharma (POLB)

26 July 2024- Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that it is voluntarily delisting its ordinary shares (“Ordinary Shares”) from trading on the OTCQB Market due to low trading volume and the associated administrative requirements. The Company’s last day of trading on the OTCQB Market will be Monday 29 July 2024. Poolbeg…

Continue reading

#TSP TruSpine Technologies PLC – Convertible Loan Note, Debenture and AGM Update March 28, 2024 – Posted in: TruSpine Plc (TSP)

TruSpine Technologies Plc, the medical device company focused on the spinal (vertebral) stabilisation market, provides an update in relation (1) unsecured Convertible Loan Note instrument announced on 14 March 2024, (2) the Debenture announced on 27 February 2023 and (3) the 2023 Annual General Meeting (“2023 AGM”).   Convertible Loan Note   As announced on 14 March 2024, the Company constituted an unsecured Convertible Loan Note instrument for the issue of loan notes (“CLN” or…

Continue reading

#HVO hVIVO PLC – Proposed Secondary Placing of Ordinary Shares February 14, 2024 – Posted in: hVIVO (HVO)

hVIVO plc (AIM & Euronext: HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that it has been informed by certain Directors of the Company of their intention to sell, in aggregate, not less than 14,000,000 ordinary shares of 0.1 pence each (“Ordinary Shares”) in the capital of Company (the “Placing Shares”), representing approximately 25% of their current shareholding, at a price of 28 pence per Placing…

Continue reading

#VELA Vela Technologies PLC investee co. #CSFS Cornerstone FS PLC – PDMR Shareholding, Issue of Equity and TVR February 6, 2023 – Posted in: Vela Technologies Plc (VELA)

Further to the Company’s announcement of 5 August 2022, Cornerstone FS Plc (AIM: CSFS), the cloud-based provider of international payment, currency risk management and electronic account services to SMEs, announces the issue and allotment of  ordinary shares of 1 penny each in the capital of the Company (“Ordinary Shares”) to a PDMR and a significant shareholder of the Company. This follows the receipt of permission from the Financial Conduct Authority (“FCA”) for them each to…

Continue reading

#VELA Vela Technologies PLC – Investment in Ethernity Networks Ltd January 20, 2023 – Posted in: Vela Technologies Plc (VELA)

The Board of Vela (AIM: VELA), an AIM-quoted investing company focused on early stage and pre-IPO disruptive technology investments, announces that the Company has invested £49,000 in Ethernity Networks Ltd (“Ethernity”) through the purchase of 700,000 ordinary shares. The investment has been made as part of a £1.55 million placing undertaken by Ethernity, details of which were announced by Ethernity on 17 January 2023. Further information on Ethernity Ethernity is a leading provider of networking…

Continue reading

#VELA Vela Technologies PLC investee co. #TSP TruSpine Technologies PLC – Bridge Loan and £2.4m Investment Letter of Intent January 3, 2023 – Posted in: Vela Technologies Plc (VELA)

TruSpine Technologies Plc, the medical device company focused on the spinal (vertebral) stabilisation market, announces that it has entered into a £200,000 bridging loan facility (“Bridge Loan”) together with a non-binding letter of intent (“LOI”) to provide £2.4m staged equity funding over three tranches (“Investment Agreement”) with a UK investment group (the “Investment Group”).   Terms of the Bridge Loan: Bridge Loan facility entered with Investment Group –      £200,000 to be available immediately –      8%…

Continue reading